✦ LIBER ✦

P139 Favourable therapeutic effect of rituximab in the treatment of patients with advanced gastrointestinal non-Hodgkin's lymphoma

✍ Scribed by J.L. Iványi; É. Marton; M. Plander; G. Gyánó; Cs. Tóth

Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 58 KB
Volume: 21
Category: Article
ISSN: 0268-960X
DOI: 10.1016/s0268-960x(07)70217-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rituximab plus ASHAP for the treatment o

Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin’s lymphoma: a single-centre study of 20 patients

✍ Semra Aydin; Ulrich Dührsen; Holger Nückel 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 125 KB

The effect of optimal treatment on elder

The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates

✍ F. Peters; M. Fickers; F. Erdkamp; J. Wals; J. Wils; H. Schouten 📂 Article 📅 2001 🏛 Springer 🌐 English ⚖ 48 KB

A phase II trial of teniposide (VM 26) i

A phase II trial of teniposide (VM 26) in advanced non-Hodgkin's lymphoma, with emphasis on the treatment of elderly patients

✍ Dr. Umberto Tirelli; Antonino Carbone; Diana Crivellari; Rachele Volpe; Giovanni 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 418 KB 👁 3 views

Anthracycline-fludarabine-containing reg

Anthracycline-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma

✍ Stefano Luminari; Luigi Marcheselli; Stefano Sacchi; Samantha Pozzi; Alessia Bar 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 153 KB 👁 1 views

Possible efficacy of lamivudine treatmen

Possible efficacy of lamivudine treatment to prevent hepatitis B virus reactivation due to rituximab therapy in a patient with non-Hodgkin's lymphoma

✍ Y. Tsutsumi; J. Tanaka; T. Kawamura; T. Miura; H. Kanamori; S. Obara; M. Asaka; 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 106 KB

CEOP treatment results and validity of t

CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma

✍ C. S. Chim; Y. L. Kwong; A. K. W. Lie; C. K. Lee; R. Liang 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 125 KB 👁 2 views

From 1991 to 1997, we have treated 78 newly diagnosed patients with aggressive non-Hodgkin's lymphoma with a modified CHOP regimen in which epirubicin (60 mg/m 2 ) was used in place of doxorubicin (50 mg/m 2 ), i.e. CEOP (cyclophosphamide, epirubicin, vincristine and prednisolone). The median age wa